People Background Check
Find People:

Benjamin S Szwergold, Age 7326 Pleasant St, West Lebanon, NH 03784

Get Report
Known as:
Ben S Szwergold
Related to:
Karen J Rothschild 70 Noam H Szwergold 40 Robert R Rothschild Susan H Rothschild 91 Nava R Szwergold 35

Benjamin Szwergold Phones & Addresses

26 Pleasant St, West Lebanon, NH 03784 (603) 298-9797

29 Village Grn, West Lebanon, NH 03784 (603) 298-9797

2 N Park St, Hanover, NH 03755 (603) 643-8152

21 E Mcpherson St, Philadelphia, PA 19119 (215) 242-8380

Cedarhurst, NY

Brooklyn, NY

Teaneck, NJ

Lebanon, NH

Show more

Mentions for Benjamin S Szwergold

Resumes

Resumes

Benjamin Szwergold Photo 1

Retired But Active Research Biochemist

Position:
Semiretired at YBH of Passaic
Location:
Greater Boston Area
Industry:
Biotechnology
Work:
YBH of Passaic - Lebanon, NH since Jan 2013
Semiretired Dartmouth Medical School Sep 1997 - Sep 2007
Research Associate Professor
Education:
Columbia University, Graduate School of Arts and Sciences 1979 - 1984
Skills:
Teaching, Physics, Science, Physical Sciences, Biochemistry, Biology, Chemistry
Benjamin Szwergold Photo 2

Independent Health, Wellness And Fitness Professional

Location:
Groraum New York City und Umgebung
Industry:
Gesundheit, Wellness & Fitness

Publications

Us Patents

Treatment For Complications Of Type 2 Diabetes

US Patent:
6498193, Dec 24, 2002
Filed:
Dec 13, 2000
Appl. No.:
09/735683
Inventors:
Paul J. Beisswenger - Hanover NH
Benjamin S. Szwergold - Hanover NH
Assignee:
Trustees of Dartmouth College - Hanover NH
International Classification:
A61K 31155
US Classification:
514635
Abstract:
A method is disclosed of lowering plasma levels of -dicarbonyl precursors of advanced glycation end-products, such as methylglyoxal, in a patient having type 2 diabetes by administrating metformin in a dosage from twenty-five to fifty percent in excess of its antidiabetic therapeutic regimen. The high dosage of metformin acts to reduce plasma levels of -dicarbonyl compounds by a mechanism distinct from that whereby it exerts its antidiabetic activity.

Method For Inhibiting Or Reversing Non-Enzymatic Glycation

US Patent:
8138227, Mar 20, 2012
Filed:
Jun 1, 2007
Appl. No.:
11/756689
Inventors:
Benjamin Szwergold - West Lebanon NH,
Assignee:
Trustees of Dartmouth College - Hanover NH
International Classification:
A61K 31/13
US Classification:
514665, 514866
Abstract:
The present invention relates to a method for inhibiting or reversing non-enzymatic glycation of the first intermediate of a biological moiety using an α-thiolamine. By inhibiting or reversing non-enzymatic glycation of the biological moiety, conditions such as aging and diabetic complications can be prevented or reversed.

Compounds And Methods For Therapeutic Intervention In Preventing Diabetic Complications And Procedures For Assessing A Diabetic's Risk Of Developing Complications And Determining The Efficacy Of Therapeutic Intervention

US Patent:
6004958, Dec 21, 1999
Filed:
Feb 5, 1997
Appl. No.:
8/794433
Inventors:
Truman R. Brown - Laverock PA
Francis Kappler - Philadelphia PA
Benjamin Szwergold - Philadelphia PA
Sundeep Lal - Lansdale PA
Bangying Su - Philadelphia PA
Assignee:
Fox Chase Cancer Center - Philadelphia PA
International Classification:
A61K 31535
A61K 3119
A61K 3113
A61K 31045
US Classification:
5142388
Abstract:
The present invention is based on the discovery of a metabolic pathway in which a specific kinase converts fructose-lysine into fructose-lysine-3-phosphate in an ATP dependent reaction. Fructose-lysine-3-phosphate (FL3P) is then broken down to form free lysine, inorganic phosphate and 3-deoxyglucosone (3DG), the latter being a reactive protein modifying agent. 3DG can be detoxified by reduction to 3-deoxyfructose (3DF), or it can react with endogenous proteins to form advanced glycation end-product modified proteins (AGE-proteins), which are believed to be a cause of diabetic complications. Disclosed is a class of compounds which inhibit the action of FL3P kinase in the above-mentioned pathway. Also disclosed are therapeutic methods of using such inhibitors to reduce formation of AGE-proteins and thereby lessen, reduce and delay diabetic complications, as well as methods for assessing a diabetic's risk of developing complications and for determining the efficacy of the disclosed inhibitor therapy by measuring the ratio of 3DG to 3DF in a biological sample following an oral dose of a fructose-lysine-containing food product.

Method For Assessing Risk Of Diabetes-Associated Pathologic Conditions And Efficacy Of Therapies For Such Conditions

US Patent:
5231031, Jul 27, 1993
Filed:
Aug 17, 1990
Appl. No.:
7/568919
Inventors:
Benjamin S. Szwergold - Philadelphia PA
Truman R. Brown - Bedminster NJ
Francis Kappler - Philadelphia PA
Aqqaluk Peterson - Copenhagen,
Assignee:
Fox Chase Cancer Center - Philadelphia PA
International Classification:
G01N 3348
G01N 2408
US Classification:
436 63
Abstract:
Concentrations of one or more carbohydrates phosphorylated at a secondary hydroxyl, including fructose-3-phosphate and sorbitol-3-phosphate, in biological tissue or cells of diabetic patients are determined by. sup. 31 P NMR Spectroscopy, High Performance Liquid Chromatography (HPLC) or other appropriate analytical techniques. Elevated levels of such phosphorylated carbohydrates, relative to a prescribed standard or threshold level, are associated with an increased risk for developing the degenerative complications of diabetes. A method is provided for determining the relative concentrations of such phosphorylated carbohydrates, whereby the relative risk of a patient for the development of diabetic complications and the efficacy of therapeutic intervention in prevention of such complications may be assessed.

Possible Relatives

Benjamin M Johnston  Benjamin L Stanford  Benjamin B Joiner  Benjamin J Stanton  Benjamin O Staples  Benjamin C Stapleton  Benjamin E Stark  Benjamin R Stauffer  Benjamin J Stein  Benjamin Mcgraw 

All data offered is derived from public sources. We do not verify or evaluate each piece of data, and makes no warranties or guarantees about any of the information offered. We do not possess or have access to secure or private financial information. People Background Check is not a credit reporting agency and does not offer consumer reports. None of the information offered by People Background Check is to be considered for purposes of determining any entity or person's eligibility for credit, insurance, employment, housing, or for any other purposes covered under the FCRA.